Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2017

View Archived Issues

ALX-1141 to enter clinical development for the treatment of osteoarthritis

Rasagiline does not add benefit to standard therapy in ALS trial

Proof-of-concept study finds potassium-channel opener ezogabine ameliorates depression

Complete disease correction using gene therapy in novel model of muccopolysaccharidosis type IIID

Phase I results for CPI-613 plus modified FOLFIRINOX in patients with metastatic pancreatic cancer

Cariprazine granted positive opinion in Europe for the treatment of schizophrenia

FDA grants rare pediatric disease designation for EF-022

AC Immune enters research collaboration with Essex Bio-Technology

EMA committee gives positive opinion to brodalumab for plaque psoriasis

eFFECTOR Therapeutics identifies novel MNK1/2 inhibitors

Emmyon patents new furostan-3-ol derivatives

NDUFS7 gene polymorphism tied to obsessive-compulsive disorder risk

University of Dundee and Corbin Therapeutics agree to identify USP15 inhibitors

Shire gives update on phase I/II study of SHP-656 for hemophilia A

Xynomic Pharma and UCSF to conduct phase II/III study of abexinostat in RCC

FDA approves Actemra as first therapy to treat giant cell arteritis

Nektar and Takeda to explore combinations of NKTR-214

Otsuka reports topline results from phase III study of tolvaptan in ADPKD

ViaCyte cleared to begin trial of PEC-Direct in U.S. and Canada

EMA committee recommends approval of Oxervate for neurotrophic keratitis

Celgene reports positive results from RADIANCE study of ozanimod

New mouse model of pulmonary hypertension induced by oxidized lipids presented

FDA approves Kevzara for rheumatoid arthritis

Zealand reports phase IIa results for dasiglucagon in type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...